Your browser is no longer supported. Please, upgrade your browser.
Settings
ENLV Enlivex Therapeutics Ltd. daily Stock Chart
ENLV [NASD]
Enlivex Therapeutics Ltd.
Index- P/E- EPS (ttm)-12.84 Insider Own0.95% Shs Outstand10.00M Perf Week26.73%
Market Cap284.90M Forward P/E- EPS next Y- Insider Trans- Shs Float5.98M Perf Month75.88%
Income-5.90M PEG- EPS next Q- Inst Own14.80% Short Float0.33% Perf Quarter186.91%
Sales- P/S- EPS this Y32.60% Inst Trans- Short Ratio1.75 Perf Half Y252.60%
Book/sh27.84 P/B1.02 EPS next Y- ROA- Target Price9.00 Perf Year121.20%
Cash/sh1.36 P/C20.95 EPS next 5Y- ROE- 52W Range6.19 - 28.49 Perf YTD360.23%
Dividend- P/FCF- EPS past 5Y-24.10% ROI- 52W High-6.48% Beta1.84
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin- 52W Low330.42% ATR1.71
Employees19 Current Ratio3.80 Sales Q/Q- Oper. Margin- RSI (14)73.19 Volatility8.85% 8.83%
OptionableNo Debt/Eq0.00 EPS Q/Q-135.90% Profit Margin- Rel Volume3.18 Prev Close28.49
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume11.33K Price26.65
Recom- SMA2025.92% SMA5069.72% SMA200132.44% Volume20,241 Change-6.48%
Jul-16-19 07:30AM  Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange GlobeNewswire +9.75%
Jun-18-19 07:30AM  Australian Patent Office Grants New Patent Covering Enlivexs AllocetraTM Immunotherapy Treatment GlobeNewswire
Jun-06-19 07:30AM  Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients GlobeNewswire -8.34%
May-30-19 08:35AM  Enlivex Therapeutics to Present at The 2019 Jefferies Global Healthcare Conference GlobeNewswire
Apr-18-19 08:15AM  IMMUNOTHERAPY COMPANY ENLIVEX THERAPEUTICS SELECTED TO RECEIVE AN ADDITIONAL $1 MILLION GRANT BY THE ISRAEL INNOVATION AUTHORITY FOR ITS SEPSIS CLINICAL PROGRAM GlobeNewswire -5.59%
Apr-08-19 07:30AM  IMMUNOTHERAPY COMPANY ENLIVEX THERAPEUTICS COMPLETES PREVIOUSLY ANNOUNCED FINANCING PRICED AT $12.25 PER SHARE, RAISING A TOTAL OF APPROXIMATELY $8.4 MILLION GlobeNewswire
Apr-04-19 09:31AM  ENLIVEX THERAPEUTICS TO PRESENT AT THE 2019 H.C. WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE GlobeNewswire
Mar-26-19 07:30AM  Immunotherapy Company Enlivex Therapeutics Announces Nasdaq Listing Under Symbol ENLV and Closing of Private Placement of Ordinary Shares Priced at $12.25 Per Share GlobeNewswire -10.45%
Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate for the prevention of complications post bone marrow transplantations; treatment of patients that do not respond to steroid treatment upon occurrence of graft vs host disease post bone marrow transplantations; and prevention of cytokine storms, organ damage, and multiple organ failure in sepsis patients. The company also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.